drugset / Trial / NCT06071013
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/2
Recruiting
20 enrolled
China Medical University Hospital
China Medical University, Taiwan · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
Timeline
- Start
- 2024-02-23
- Primary completion
- 2026-08-27
- Completion
- 2026-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | — | Oral |
| Subject | Erlotinib | Small molecule | — | Oral |
| Subject | Gefitinib | Small molecule | — | Oral |
| Subject | Nintedanib | Small molecule | — | Oral |
| Subject | Osimertinib | Small molecule | — | Oral |